Skip to main content
IONS
NASDAQ Life Sciences

Ionis Pharmaceuticals Exceeds TRYNGOLZA Sales, Doubles Peak Sales Guidance to >$2B, and Highlights Strong 2026 Pipeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$80.4
Mkt Cap
$13.207B
52W Low
$23.95
52W High
$86.15
52W Position info
236% above low
Off High info
6.7% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IONS has more than doubled off its 52-week low of $23.95.

Summary

Ionis Pharmaceuticals announced preliminary 2025 U.S. net product sales for TRYNGOLZA that outperformed expectations, significantly increased its peak sales guidance for the drug, and detailed a robust pipeline with multiple anticipated launches and data readouts in 2026.


Key Events · Product Development and Regulatory · IONS

  • TRYNGOLZA Sales Outperform

    Preliminary 2025 U.S. net product sales for TRYNGOLZA reached $105 million, exceeding expectations for the first FDA-approved treatment for FCS.

  • Peak Sales Guidance Doubled

    Annual peak net sales guidance for TRYNGOLZA in severe hypertriglyceridemia (sHTG) increased from >$1 billion to >$2 billion, based on strong product profile and positive Phase 3 data.

  • Positive Bepirovirsen Phase 3 Results

    Announced positive topline results for bepirovirsen in chronic hepatitis B, demonstrating a statistically significant and clinically meaningful functional cure rate, with planned regulatory submissions in 2026.

  • Robust 2026 Pipeline Catalysts

    Anticipates two new independent launches (olezarsen for sHTG, zilganersen for Alexander disease), five Phase 3 readouts, and four NDA submissions in 2026 across its owned and partnered programs.


Analysis · IONS · Life Sciences

This 8-K filing signals strong operational momentum and a significantly improved outlook for Ionis Pharmaceuticals. The preliminary sales for TRYNGOLZA exceeding expectations, coupled with a doubling of its peak sales guidance for severe hypertriglyceridemia, indicates a much larger market opportunity and potential revenue stream for a key asset. The positive Phase 3 results for bepirovirsen further de-risk a partnered program, while the numerous upcoming regulatory submissions and launches in 2026 suggest a transformative year for the company's commercial and clinical pipeline. Investors should view this as a strong validation of the company's strategy and pipeline execution, potentially leading to accelerated revenue growth and a path to cash flow breakeven by 2028.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 46.6% of the 1552 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.23%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IONS was trading at $80.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $23.95 to $86.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IONS - Latest Insights

IONS
Oct 23, 2026, 1:41 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.93
Real-time Price: $39.20 info
Change: -$3.73 (-9%) info
Market Cap: $6.551B info
IONS
Oct 20, 2026, 9:20 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $45.20
Real-time Price: $39.20 info
Change: -$6.00 (-13%) info
Market Cap: $6.551B info
IONS
Oct 16, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.56
Real-time Price: $39.20 info
Change: -$4.36 (-10%) info
Market Cap: $6.551B info
IONS
Sep 23, 2026, 1:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.75
Real-time Price: $39.20 info
Change: -$6.55 (-14%) info
Market Cap: $6.551B info
IONS
Sep 22, 2026, 8:36 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $46.42
Real-time Price: $39.20 info
Change: -$7.22 (-16%) info
Market Cap: $6.551B info